Structure Therapeutics Appoints New COO and General Counsel Amid Advancing Obesity Drug Pipeline
Structure Therapeutics Appoints Matthew Lang, J.D., as Chief Operating Officer and General Counsel
Key Strategic Leadership Addition as Company Advances Lead Obesity Drug into Pivotal Phase 3 Trials
Key Points
- Matthew Lang, J.D., appointed as Chief Operating Officer and General Counsel, effective April 14, 2026.
- Lang brings over 15 years of executive leadership in the biopharmaceutical sector, with significant experience in legal, corporate strategy, compliance, risk management, and business development.
- Lang played a pivotal role in Metsera’s acquisition by Pfizer for up to \$10 billion, and has held leadership positions at Lyell Immunopharma, Myovant Sciences, and Gilead Sciences.
- Strategic appointment comes as Structure Therapeutics prepares to advance its lead oral small molecule obesity drug, aleniglipron, into Phase 3 clinical trials.
- Company continues to build a robust pipeline of oral therapies targeting chronic metabolic diseases, aiming to address scalability limitations of current biologic and peptide treatments.
Details for Investors
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing novel oral small molecule drugs for metabolic diseases, has announced a key leadership addition. The company has appointed Matthew Lang, J.D., as Chief Operating Officer and General Counsel. This move signals a significant strengthening of Structure’s executive team at a critical juncture, as the company advances its lead candidate, aleniglipron, into Phase 3 development targeting the competitive obesity treatment landscape.
Lang’s credentials are noteworthy: he was most recently Chief Legal Officer and Secretary at Metsera, Inc., where he was instrumental in the company’s acquisition by Pfizer in a deal valued up to \$10 billion. Prior to that, he was Chief Business and Legal Officer at Lyell Immunopharma, Inc., and played a crucial role at Myovant Sciences during the Phase 3 development, global approval, and commercialization of Myfembree® and Orgovyx®. He also served as Managing Director and General Manager of Myovant’s European operations in Basel, Switzerland, overseeing all ex-US business functions. Earlier, he held ascending roles at Gilead Sciences and began his career as an attorney at Dechert LLP. Lang holds a B.A. in Classical Studies from Queen’s University and a J.D. from the University of Pennsylvania Law School.
Raymond Stevens, Ph.D., CEO of Structure Therapeutics, commented: “Matt is a proven leader with a strong track record of guiding organizations through growth and transformation. His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team.”
Matthew Lang added: “I am excited to join Structure Therapeutics at this important stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape. The company’s mission and differentiated portfolio represent a compelling opportunity to deliver a complete pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the company’s operational foundation, execute on strategic priorities, and drive long-term value.”
What Shareholders Need to Know
-
This appointment could be price sensitive. Lang’s track record, particularly his role in a \$10 billion acquisition by Pfizer and involvement in multiple successful product launches and large-scale transactions, could boost investor confidence in Structure Therapeutics’ future strategic execution and deal-making ability.
-
Progression to Phase 3 clinical trials for aleniglipron is a major milestone that could significantly impact the company’s valuation, especially in the context of the competitive and high-growth obesity treatment market.
-
Structure’s pipeline includes several oral small molecule therapies targeting GPCRs, designed to overcome the limitations of biologic and peptide drugs, potentially expanding market reach and scalability.
-
Forward-looking statements highlight risks, including potential delays in clinical studies, regulatory uncertainties, and the need for sufficient funding to achieve development goals. Investors should review these risks in the company’s SEC filings.
About Structure Therapeutics
Structure Therapeutics is a science-driven, clinical-stage biopharma company leveraging structure-based drug discovery to develop innovative oral treatments for chronic metabolic diseases. Its oral GPCR-targeted pipeline aims to address significant unmet medical needs and scalability limitations of current therapies, with a focus on delivering more accessible obesity treatments worldwide.
Contact Information
Disclaimer
This article contains forward-looking statements that are subject to risks and uncertainties, including those related to clinical development, regulatory approvals, and commercialization of product candidates. Actual results may differ materially from those anticipated. Investors should review the company’s filings with the SEC for further information regarding these risks. This article is for informational purposes only and does not constitute investment advice.
View Structure Therapeutics Inc. Historical chart here
